JPH01500513A - 特異的興奮性アミノ酸神経伝達物質受容体の拮抗物質 - Google Patents

特異的興奮性アミノ酸神経伝達物質受容体の拮抗物質

Info

Publication number: JPH01500513A
Authority: JP; Japan
Prior art keywords: acid; substance; compound; amino; phenyl
Prior art date: 1986-04-09
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP62501875A

Other languages

English (en)

Japanese (ja)

Inventor

レツォタルスキー、ジャヌツ　ワクロウ

ハドキンス、ロバート　リー

グゼウスカ、マリア　エリザベス

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Individual

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1986-04-09

Filing date

1987-02-25

Publication date

1989-02-23

1987-02-25 Application filed by Individual filed Critical Individual

1989-02-23 Publication of JPH01500513A publication Critical patent/JPH01500513A/ja

Status Pending legal-status Critical Current

Links

230000002461 excitatory amino acid Effects 0.000 title claims description 11
239000003257 excitatory amino acid Substances 0.000 title claims description 11
102000004108 Neurotransmitter Receptors Human genes 0.000 title claims description 5
108090000590 Neurotransmitter Receptors Proteins 0.000 title claims description 5
239000005557 antagonist Substances 0.000 title description 11
206010010904 Convulsion Diseases 0.000 claims description 25
239000002253 acid Substances 0.000 claims description 25
239000000126 substance Substances 0.000 claims description 23
150000003839 salts Chemical class 0.000 claims description 12
241001465754 Metazoa Species 0.000 claims description 11
-1 pivaloyloxymethyl ester Chemical class 0.000 claims description 9
239000003085 diluting agent Substances 0.000 claims description 5
239000002858 neurotransmitter agent Substances 0.000 claims description 5
206010015037 epilepsy Diseases 0.000 claims description 4
239000008194 pharmaceutical composition Substances 0.000 claims description 4
230000003389 potentiating effect Effects 0.000 claims description 4
230000036461 convulsion Effects 0.000 claims description 3
239000002464 receptor antagonist Substances 0.000 claims description 3
229940044551 receptor antagonist Drugs 0.000 claims description 3
CNBNYFVTSLNOCY-UHFFFAOYSA-N 2-amino-3-[2-(2-phosphonoethyl)phenyl]propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC=C1CCP(O)(O)=O CNBNYFVTSLNOCY-UHFFFAOYSA-N 0.000 claims description 2
125000000217 alkyl group Chemical group 0.000 claims description 2
125000004093 cyano group Chemical group *C#N 0.000 claims description 2
239000000411 inducer Substances 0.000 claims description 2
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
238000011282 treatment Methods 0.000 claims 4
239000003937 drug carrier Substances 0.000 claims 2
RPSYNMUEPPFSLK-UHFFFAOYSA-N 2-amino-3-[2-(3-phosphonopropyl)phenyl]propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC=C1CCCP(O)(O)=O RPSYNMUEPPFSLK-UHFFFAOYSA-N 0.000 claims 1
MRGUIJVNFRTRSF-UHFFFAOYSA-N 2-amino-3-[2-(phosphonomethyl)phenyl]propanoic acid Chemical group OC(=O)C(N)CC1=CC=CC=C1CP(O)(O)=O MRGUIJVNFRTRSF-UHFFFAOYSA-N 0.000 claims 1
BQWMQNSPGIZJTP-UHFFFAOYSA-N 2-amino-5-[2-(phosphonomethyl)phenyl]pentanoic acid Chemical group OC(=O)C(N)CCCC1=CC=CC=C1CP(O)(O)=O BQWMQNSPGIZJTP-UHFFFAOYSA-N 0.000 claims 1
125000003277 amino group Chemical group 0.000 claims 1
229940124277 aminobutyric acid Drugs 0.000 claims 1
SZPMDMCIUCPCIC-UHFFFAOYSA-N carbamoyloxymethyl 2,2-dimethylpropanoate Chemical compound CC(C)(C)C(=O)OCOC(N)=O SZPMDMCIUCPCIC-UHFFFAOYSA-N 0.000 claims 1
239000000969 carrier Substances 0.000 claims 1
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical group NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims 1
125000005843 halogen group Chemical group 0.000 claims 1
125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
239000000463 material Substances 0.000 claims 1
230000035807 sensation Effects 0.000 claims 1
150000001875 compounds Chemical class 0.000 description 65
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 51
239000003921 oil Substances 0.000 description 33
235000019198 oils Nutrition 0.000 description 33
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 24
230000002829 reductive effect Effects 0.000 description 24
102000005962 receptors Human genes 0.000 description 21
108020003175 receptors Proteins 0.000 description 21
238000012360 testing method Methods 0.000 description 21
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
239000000203 mixture Substances 0.000 description 16
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
VLSMHEGGTFMBBZ-UHFFFAOYSA-N alpha-Kainic acid Natural products CC(=C)C1CNC(C(O)=O)C1CC(O)=O VLSMHEGGTFMBBZ-UHFFFAOYSA-N 0.000 description 14
229950006874 kainic acid Drugs 0.000 description 14
239000007787 solid Substances 0.000 description 14
238000003756 stirring Methods 0.000 description 14
230000000694 effects Effects 0.000 description 13
VLSMHEGGTFMBBZ-OOZYFLPDSA-N kainic acid Chemical compound CC(=C)[C@H]1CN[C@H](C(O)=O)[C@H]1CC(O)=O VLSMHEGGTFMBBZ-OOZYFLPDSA-N 0.000 description 13
239000000243 solution Substances 0.000 description 13
BDZBKCUKTQZUTL-UHFFFAOYSA-N triethyl phosphite Chemical compound CCOP(OCC)OCC BDZBKCUKTQZUTL-UHFFFAOYSA-N 0.000 description 12
229940079593 drug Drugs 0.000 description 11
239000003814 drug Substances 0.000 description 11
238000000921 elemental analysis Methods 0.000 description 11
238000000034 method Methods 0.000 description 11
230000009870 specific binding Effects 0.000 description 11
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 10
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 9
239000000872 buffer Substances 0.000 description 9
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 8
239000001961 anticonvulsive agent Substances 0.000 description 8
239000003480 eluent Substances 0.000 description 8
238000002844 melting Methods 0.000 description 8
230000008018 melting Effects 0.000 description 8
241000699670 Mus sp. Species 0.000 description 7
210000004556 brain Anatomy 0.000 description 7
238000006243 chemical reaction Methods 0.000 description 7
238000001816 cooling Methods 0.000 description 7
238000010898 silica gel chromatography Methods 0.000 description 7
DDOQBQRIEWHWBT-VKHMYHEASA-N (2S)-2-amino-4-phosphonobutanoic acid Chemical compound OC(=O)[C@@H](N)CCP(O)(O)=O DDOQBQRIEWHWBT-VKHMYHEASA-N 0.000 description 6
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 6
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical class OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 6
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 6
230000001773 anti-convulsant effect Effects 0.000 description 6
229960003965 antiepileptics Drugs 0.000 description 6
239000000543 intermediate Substances 0.000 description 6
239000003446 ligand Substances 0.000 description 6
239000011541 reaction mixture Substances 0.000 description 6
159000000000 sodium salts Chemical class 0.000 description 6
AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 5
239000006227 byproduct Substances 0.000 description 5
238000004821 distillation Methods 0.000 description 5
229920006226 ethylene-acrylic acid Polymers 0.000 description 5
231100000318 excitotoxic Toxicity 0.000 description 5
230000003492 excitotoxic effect Effects 0.000 description 5
239000002904 solvent Substances 0.000 description 5
210000001519 tissue Anatomy 0.000 description 5
101710138657 Neurotoxin Proteins 0.000 description 4
GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 4
230000027455 binding Effects 0.000 description 4
125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
238000001914 filtration Methods 0.000 description 4
239000002581 neurotoxin Substances 0.000 description 4
231100000618 neurotoxin Toxicity 0.000 description 4
230000001681 protective effect Effects 0.000 description 4
229910052717 sulfur Inorganic materials 0.000 description 4
239000006228 supernatant Substances 0.000 description 4
238000005292 vacuum distillation Methods 0.000 description 4
MGRVRXRGTBOSHW-UHFFFAOYSA-N (aminomethyl)phosphonic acid Chemical compound NCP(O)(O)=O MGRVRXRGTBOSHW-UHFFFAOYSA-N 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
229930195714 L-glutamate Natural products 0.000 description 3
XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
238000005119 centrifugation Methods 0.000 description 3
238000000354 decomposition reaction Methods 0.000 description 3
229910001873 dinitrogen Inorganic materials 0.000 description 3
238000005516 engineering process Methods 0.000 description 3
239000008187 granular material Substances 0.000 description 3
210000001320 hippocampus Anatomy 0.000 description 3
230000007062 hydrolysis Effects 0.000 description 3
238000006460 hydrolysis reaction Methods 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
238000002347 injection Methods 0.000 description 3
AJFDBNQQDYLMJN-UHFFFAOYSA-N n,n-diethylacetamide Chemical compound CCN(CC)C(C)=O AJFDBNQQDYLMJN-UHFFFAOYSA-N 0.000 description 3
229910052757 nitrogen Inorganic materials 0.000 description 3
230000009871 nonspecific binding Effects 0.000 description 3
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 3
239000002244 precipitate Substances 0.000 description 3
239000000047 product Substances 0.000 description 3
GJAWHXHKYYXBSV-UHFFFAOYSA-N quinolinic acid Chemical compound OC(=O)C1=CC=CN=C1C(O)=O GJAWHXHKYYXBSV-UHFFFAOYSA-N 0.000 description 3
229910052708 sodium Inorganic materials 0.000 description 3
239000011734 sodium Substances 0.000 description 3
IRJCBFDCFXCWGO-SCSAIBSYSA-N (2r)-2-azaniumyl-2-(3-oxo-1,2-oxazol-5-yl)acetate Chemical compound [O-]C(=O)[C@H]([NH3+])C1=CC(=O)NO1 IRJCBFDCFXCWGO-SCSAIBSYSA-N 0.000 description 2
FWYHRXVCIWHPMO-UHFFFAOYSA-N 1-(2-bromoethyl)-2-(bromomethyl)benzene Chemical compound BrCCC1=CC=CC=C1CBr FWYHRXVCIWHPMO-UHFFFAOYSA-N 0.000 description 2
GWSTUUNCARBYBG-UHFFFAOYSA-N 2-ethylbutanamide;propanedioic acid Chemical compound OC(=O)CC(O)=O.CCC(CC)C(N)=O GWSTUUNCARBYBG-UHFFFAOYSA-N 0.000 description 2
FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
102100022006 Cell division cycle protein 123 homolog Human genes 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
108010016626 Dipeptides Proteins 0.000 description 2
101000897353 Homo sapiens Cell division cycle protein 123 homolog Proteins 0.000 description 2
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
IRJCBFDCFXCWGO-UHFFFAOYSA-N Ibotenic acid Natural products OC(=O)C(N)C1=CC(=O)NO1 IRJCBFDCFXCWGO-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
ASNFTDCKZKHJSW-REOHCLBHSA-N Quisqualic acid Chemical compound OC(=O)[C@@H](N)CN1OC(=O)NC1=O ASNFTDCKZKHJSW-REOHCLBHSA-N 0.000 description 2
239000007983 Tris buffer Substances 0.000 description 2
239000000556 agonist Substances 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
RDHPKYGYEGBMSE-UHFFFAOYSA-N bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
150000001768 cations Chemical class 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
HERPVHLYIHBEFW-ZETCQYMHSA-N diethyl (2s)-2-aminopentanedioate Chemical compound CCOC(=O)CC[C@H](N)C(=O)OCC HERPVHLYIHBEFW-ZETCQYMHSA-N 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
239000012153 distilled water Substances 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
230000002964 excitative effect Effects 0.000 description 2
235000013922 glutamic acid Nutrition 0.000 description 2
239000004220 glutamic acid Substances 0.000 description 2
MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 2
229910052739 hydrogen Inorganic materials 0.000 description 2
238000011534 incubation Methods 0.000 description 2
CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 2
230000003902 lesion Effects 0.000 description 2
210000003141 lower extremity Anatomy 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
239000012528 membrane Substances 0.000 description 2
210000003205 muscle Anatomy 0.000 description 2
229910052760 oxygen Inorganic materials 0.000 description 2
239000008188 pellet Substances 0.000 description 2
210000001871 perforant pathway Anatomy 0.000 description 2
229910052698 phosphorus Inorganic materials 0.000 description 2
230000004044 response Effects 0.000 description 2
239000013049 sediment Substances 0.000 description 2
239000012265 solid product Substances 0.000 description 2
239000004094 surface-active agent Substances 0.000 description 2
239000000375 suspending agent Substances 0.000 description 2
210000000225 synapse Anatomy 0.000 description 2
201000008914 temporal lobe epilepsy Diseases 0.000 description 2
238000013519 translation Methods 0.000 description 2
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
BTBLOIFADLKOQZ-UHFFFAOYSA-N 1-(bromomethyl)-2-(3-bromopropyl)benzene Chemical compound BrCCCC1=CC=CC=C1CBr BTBLOIFADLKOQZ-UHFFFAOYSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
ZWXRLXXQIGPUBG-UHFFFAOYSA-N 2-acetamido-2-[[2-(2-diethoxyphosphorylethyl)phenyl]methyl]-3-ethoxy-3-oxopropanoic acid Chemical compound CCOC(=O)C(C(O)=O)(NC(C)=O)CC1=CC=CC=C1CCP(=O)(OCC)OCC ZWXRLXXQIGPUBG-UHFFFAOYSA-N 0.000 description 1
HOECQYSWWGFBOT-UHFFFAOYSA-N 2-acetamido-3-ethoxy-2-methyl-3-oxopropanoic acid Chemical compound CCOC(=O)C(C)(C(O)=O)NC(C)=O HOECQYSWWGFBOT-UHFFFAOYSA-N 0.000 description 1
JRXXEXVXTFEBIY-UHFFFAOYSA-N 3-ethoxypropanoic acid Chemical compound CCOCCC(O)=O JRXXEXVXTFEBIY-UHFFFAOYSA-N 0.000 description 1
206010001497 Agitation Diseases 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
206010003591 Ataxia Diseases 0.000 description 1
206010003694 Atrophy Diseases 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
201000006474 Brain Ischemia Diseases 0.000 description 1
VYMNBCBSVCPKEV-UHFFFAOYSA-M CC(C(=O)OCC)C(=O)[O-].[Na+] Chemical compound CC(C(=O)OCC)C(=O)[O-].[Na+] VYMNBCBSVCPKEV-UHFFFAOYSA-M 0.000 description 1
206010048964 Carotid artery occlusion Diseases 0.000 description 1
206010008120 Cerebral ischaemia Diseases 0.000 description 1
ASNFTDCKZKHJSW-UHFFFAOYSA-N DL-Quisqualic acid Natural products OC(=O)C(N)CN1OC(=O)NC1=O ASNFTDCKZKHJSW-UHFFFAOYSA-N 0.000 description 1
YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
208000023105 Huntington disease Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
VLSMHEGGTFMBBZ-OOZYFLPDSA-M Kainate Chemical compound CC(=C)[C@H]1C[NH2+][C@H](C([O-])=O)[C@H]1CC([O-])=O VLSMHEGGTFMBBZ-OOZYFLPDSA-M 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
206010029333 Neurosis Diseases 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical class [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
240000007817 Olea europaea Species 0.000 description 1
235000019502 Orange oil Nutrition 0.000 description 1
240000007594 Oryza sativa Species 0.000 description 1
235000007164 Oryza sativa Nutrition 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
241000282520 Papio Species 0.000 description 1
ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
SKZKKFZAGNVIMN-UHFFFAOYSA-N Salicilamide Chemical compound NC(=O)C1=CC=CC=C1O SKZKKFZAGNVIMN-UHFFFAOYSA-N 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
208000006011 Stroke Diseases 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical class [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
239000013504 Triton X-100 Substances 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
241000251539 Vertebrata <Metazoa> Species 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
MOQOOKGPCBQMCY-UHFFFAOYSA-N acetic acid;hexane Chemical compound CC(O)=O.CCCCCC MOQOOKGPCBQMCY-UHFFFAOYSA-N 0.000 description 1
MNZMECMQTYGSOI-UHFFFAOYSA-N acetic acid;hydron;bromide Chemical compound Br.CC(O)=O MNZMECMQTYGSOI-UHFFFAOYSA-N 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
229940024606 amino acid Drugs 0.000 description 1
235000001014 amino acid Nutrition 0.000 description 1
239000003194 amino acid receptor blocking agent Substances 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
230000000202 analgesic effect Effects 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
230000008485 antagonism Effects 0.000 description 1
230000003556 anti-epileptic effect Effects 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
230000000573 anti-seizure effect Effects 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
230000008840 asymmetric binding Effects 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
230000037444 atrophy Effects 0.000 description 1
239000000022 bacteriostatic agent Substances 0.000 description 1
OGBVRMYSNSKIEF-UHFFFAOYSA-L benzyl-dioxido-oxo-$l^{5}-phosphane Chemical compound [O-]P([O-])(=O)CC1=CC=CC=C1 OGBVRMYSNSKIEF-UHFFFAOYSA-L 0.000 description 1
230000006931 brain damage Effects 0.000 description 1
231100000874 brain damage Toxicity 0.000 description 1
208000029028 brain injury Diseases 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
DWPHWVJZBHLVPI-UHFFFAOYSA-N bromophosphonic acid Chemical compound OP(O)(Br)=O DWPHWVJZBHLVPI-UHFFFAOYSA-N 0.000 description 1
DUMFBEVDSSRNSM-UHFFFAOYSA-N camarin Natural products CC1(C)CCC2(CCC3(C)C(=CCC4C5(C)CCC(=O)C(C)(C)C5CC(O)C34C)C2C1)C(=O)O DUMFBEVDSSRNSM-UHFFFAOYSA-N 0.000 description 1
239000002775 capsule Substances 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
206010008118 cerebral infarction Diseases 0.000 description 1
229940047583 cetamide Drugs 0.000 description 1
125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
239000007979 citrate buffer Substances 0.000 description 1
230000002566 clonic effect Effects 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
JNGZXGGOCLZBFB-IVCQMTBJSA-N compound E Chemical compound N([C@@H](C)C(=O)N[C@@H]1C(N(C)C2=CC=CC=C2C(C=2C=CC=CC=2)=N1)=O)C(=O)CC1=CC(F)=CC(F)=C1 JNGZXGGOCLZBFB-IVCQMTBJSA-N 0.000 description 1
239000003179 convulsant agent Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
230000034994 death Effects 0.000 description 1
230000007850 degeneration Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
XRIXXWKUETUCIS-UHFFFAOYSA-N diethyl 2-acetamido-2-methylpropanedioate Chemical compound CCOC(=O)C(C)(NC(C)=O)C(=O)OCC XRIXXWKUETUCIS-UHFFFAOYSA-N 0.000 description 1
ISOLMABRZPQKOV-UHFFFAOYSA-N diethyl 2-acetamidopropanedioate Chemical compound CCOC(=O)C(NC(C)=O)C(=O)OCC ISOLMABRZPQKOV-UHFFFAOYSA-N 0.000 description 1
CVEQLWWOYIJJSD-UHFFFAOYSA-N diethyl 2-acetamidopropanedioate;sodium Chemical compound [Na].CCOC(=O)C(NC(C)=O)C(=O)OCC CVEQLWWOYIJJSD-UHFFFAOYSA-N 0.000 description 1
125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 1
RXKJFZQQPQGTFL-UHFFFAOYSA-N dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
210000005069 ears Anatomy 0.000 description 1
230000007831 electrophysiology Effects 0.000 description 1
238000002001 electrophysiology Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
150000002367 halogens Chemical class 0.000 description 1
210000004295 hippocampal neuron Anatomy 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
150000002431 hydrogen Chemical class 0.000 description 1
229910000042 hydrogen bromide Inorganic materials 0.000 description 1
239000005457 ice water Substances 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
229940102223 injectable solution Drugs 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
238000011835 investigation Methods 0.000 description 1
230000000302 ischemic effect Effects 0.000 description 1
LVPMIMZXDYBCDF-UHFFFAOYSA-N isocinchomeronic acid Chemical compound OC(=O)C1=CC=C(C(O)=O)N=C1 LVPMIMZXDYBCDF-UHFFFAOYSA-N 0.000 description 1
239000007788 liquid Substances 0.000 description 1
238000005567 liquid scintillation counting Methods 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
239000011259 mixed solution Substances 0.000 description 1
210000000653 nervous system Anatomy 0.000 description 1
101150006061 neur gene Proteins 0.000 description 1
230000004770 neurodegeneration Effects 0.000 description 1
208000015122 neurodegenerative disease Diseases 0.000 description 1
230000003088 neuroexcitatory effect Effects 0.000 description 1
230000016273 neuron death Effects 0.000 description 1
208000015238 neurotic disease Diseases 0.000 description 1
239000010502 orange oil Substances 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical class [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Chemical class 0.000 description 1
239000011574 phosphorus Substances 0.000 description 1
239000006187 pill Substances 0.000 description 1
239000011148 porous material Substances 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000011533 pre-incubation Methods 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
235000019260 propionic acid Nutrition 0.000 description 1
QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
210000004129 prosencephalon Anatomy 0.000 description 1
238000000746 purification Methods 0.000 description 1
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
238000010992 reflux Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
235000009566 rice Nutrition 0.000 description 1
238000007363 ring formation reaction Methods 0.000 description 1
231100000241 scar Toxicity 0.000 description 1
230000001953 sensory effect Effects 0.000 description 1
230000035939 shock Effects 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
MFBOGIVSZKQAPD-UHFFFAOYSA-M sodium butyrate Chemical compound [Na+].CCCC([O-])=O MFBOGIVSZKQAPD-UHFFFAOYSA-M 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000000021 stimulant Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
150000003892 tartrate salts Chemical class 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
150000005691 triesters Chemical class 0.000 description 1
RXJKFRMDXUJTEX-UHFFFAOYSA-N triethylphosphine Chemical compound CCP(CC)CC RXJKFRMDXUJTEX-UHFFFAOYSA-N 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
239000008096 xylene Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3882—Arylalkanephosphonic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3834—Aromatic acids (P-C aromatic linkage)

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Medicinal Chemistry (AREA)
Biomedical Technology (AREA)
General Chemical & Material Sciences (AREA)
Neurosurgery (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurology (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

JP62501875A 1986-04-09 1987-02-25 特異的興奮性アミノ酸神経伝達物質受容体の拮抗物質 Pending JPH01500513A (ja)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US06/849,696 US4657899A (en)	1986-04-09	1986-04-09	Antagonists of specific excitatory amino acid neurotransmitter receptors
US849,696		1986-04-09

Publications (1)

Publication Number	Publication Date
JPH01500513A true JPH01500513A (ja)	1989-02-23

Family

ID=25306304

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP62501875A Pending JPH01500513A (ja)	1986-04-09	1987-02-25	特異的興奮性アミノ酸神経伝達物質受容体の拮抗物質

Country Status (6)

Country	Link
US (1)	US4657899A (fr)
EP (1)	EP0242709A3 (fr)
JP (1)	JPH01500513A (fr)
AU (1)	AU7166787A (fr)
CA (1)	CA1297492C (fr)
WO (1)	WO1987006131A1 (fr)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5243062A (en) *	1984-10-12	1993-09-07	Ciba-Geigy Corporation	Substituted propane-phosphonous acid compounds
US5457095A (en) *	1984-10-12	1995-10-10	Ciba-Geigy Corporation	Substituted propane-phosponous acid compounds
GB8600783D0 (en) *	1986-01-14	1986-02-19	Merck Sharp & Dohme	N-methyl-d-aspartate receptor antagonists
US5051413A (en) *	1986-02-13	1991-09-24	Ciba-Geigy Corporation	Unsaturated amino acids
US5175344A (en) *	1986-02-13	1992-12-29	Ciba-Geigy Corporation	Unsaturated amino acids
US5395827A (en) *	1986-04-09	1995-03-07	Guilford Pharmaceuticals Inc.	ω-[2-(phosphonoalkyl)phenyl]-2-aminoalkanoic acids as antagonists of excitatory amino acid receptors
US4812458A (en) *	1986-09-16	1989-03-14	A/S Ferrosan	6,7-disubstituted-2,3-dihydroxyquinoxaline compounds, pharmaceutical compositions thereof, and their use as neuroleptics
US5321016A (en) *	1986-10-30	1994-06-14	Sandoz Pharmaceuticals Corp.	Use of certain substituted α-amino acids in treating stress-related psychiatric disorders
GB8625941D0 (en) *	1986-10-30	1986-12-03	Sandoz Ltd	Substituted alpha-amino acids
US4761405A (en) *	1987-03-04	1988-08-02	Nova Pharmaceutical Corporation	Antagonists of specific excitatory amino acid neurotransmitter receptors having increased potency
US4970297A (en) *	1987-03-13	1990-11-13	Syntex (U.S.A.) Inc.	Transglutaminase inhibitors
US4918064A (en) *	1987-10-21	1990-04-17	G. D. Searle & Co.	Phenyl glycines for use in reducing neurotoxic injury
US5175153A (en) *	1987-11-30	1992-12-29	Warner-Lambert Company	Substituted alpha-amino acids having pharmaceutical activity
US5190933A (en) *	1987-12-04	1993-03-02	Ciba-Geigy Corporation	Substituted propane-phosphinic acid compounds
US5300679A (en) *	1987-12-04	1994-04-05	Ciba-Geigy Corporation	Substituted propane-phosphinic acid compounds
FR2634763B1 (fr) *	1988-08-01	1991-07-12	Inst Nat Sante Rech Med	Amino-acides et peptides presentant un residu tyrosine modifiee, leur preparation et leur application comme medicaments
US4997821A (en) *	1988-10-21	1991-03-05	Cordi Alexis A	Phosphono-hydroisoquinoline compounds useful in reducing neurotoxic injury
US5177240A (en) *	1988-10-21	1993-01-05	G. D. Searle & Co.	O-phosphono(alkyl)-n-sulfonyl-phenyl-alanine derivatives useful as intermediates for preparation of phosphono-hydroisoquinolines
US5049555A (en) *	1988-12-19	1991-09-17	Nova Pharmaceutical Corporation	Antagonists of specific excitatory amino acid receptors as neuroprotectants and anxiolytics
US5100654A (en) *	1989-04-07	1992-03-31	Yale University	Phosphorylated derivatives of l-dopa and compositions and methods for increasing the melanin content in mammalian skin and hair
ATE112282T1 (de) *	1989-04-07	1994-10-15	Ciba Geigy Ag	Ungesättigte aminodicarbonsäurederivate.
US5567840A (en) *	1989-05-13	1996-10-22	Ciba-Geigy Corporation	Substituted aminoalkylphosphinic acids
US5281747A (en) *	1989-05-13	1994-01-25	Ciba-Geigy Corporation	Substituted aminoalkylphosphinic acids
US5488140A (en) *	1989-09-26	1996-01-30	Ciba-Geigy Corporation	4-substituted 2-aminoalk-3-enoic
US5294734A (en) *	1989-09-26	1994-03-15	Ciba-Geigy Corp.	4-substituted 2-aminoalk-3-enoic acids
US5716964A (en) *	1989-12-04	1998-02-10	G.D. Searle & Co.	Tetrazolyl substituted imidazo 1,2-a!pyridinylalkyl compounds for treatment of neurotoxic injury
KR910011852A (ko) *	1989-12-04	1991-08-07	폴 디. 매튜카이티스	신경독 장해 치료용 이미다조[1,2-a]피리디닐알킬 화합물
US5238958A (en) *	1990-02-26	1993-08-24	Warner-Lambert Company	Substituted α-amino acids having selected acidic moieties for use as excitatory amino acid antagonists in pharmaceuticals
US5194430A (en) *	1990-05-17	1993-03-16	Merrell Dow Pharmaceuticals Inc.	Heterocyclic-nmda antagonists
IL114631A (en) *	1990-06-22	1998-12-06	Novartis Ag	Anti-epileptic compositions containing gabab- antagonistic compounds
DE69118700D1 (de) *	1990-08-13	1996-05-15	Searle & Co	Verwendung von heterozyklischen aminoalkoholverbindungen zur herstellung eines medikaments für die behandlung von erkrankungen des zns
US5118675A (en) *	1991-02-15	1992-06-02	American Home Products Corporation	Quinoxaline phosphono-amino acids
WO1993005772A1 (fr) *	1991-09-26	1993-04-01	Nova Pharmaceutical Corporation	ACIDES φ-[2-(PHOSPHONOALKYL)PHENYL]-2-AMINO-ALCANOIQUES UTILISES COMME ANTAGONISTES DE RECEPTEURS D'ACIDES AMINES EXCITATEURS
US5200546A (en) *	1991-09-30	1993-04-06	The United States Of America As Represented By The Department Of Health And Human Services	Phosphonoalkyl phenylalanine compounds suitably protected for use in peptide synthesis
US5264607A (en) *	1991-09-30	1993-11-23	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Process of making benzylic α,α-diflurophosphonates from benzylic α-ketophosphorates
US5475129A (en) *	1991-09-30	1995-12-12	The United States Of America As Represented By The Department Of Health And Human Services	Phosphonoalkyl phenylalanine compounds suitably protected for use in peptide synthesis
US5302586A (en) *	1991-12-19	1994-04-12	G. D. Searle & Co.	Phosphonomethyl-imidazo[1,2-a]pyrimidine-2-carboxylic acid compounds for treatment of neurotoxic injury
US5252563A (en) *	1991-12-19	1993-10-12	G. D. Searle & Company	5,6,7,8-tetrahydro-imidazo[1,2-a]pyrimidine compounds for treatment of neurotoxic injury
US5216003A (en) *	1992-01-02	1993-06-01	G. D. Searle & Co.	Diacid-containing benzimidazole compounds for treatment of neurotoxic injury
US5364876A (en) *	1992-12-02	1994-11-15	Guilford Pharmaceuticals Inc.	Omega-[2-(alkyl)phenyl]-2-aminoalkanoic acids as antagonists of excitatory amino acid receptors
US5331001A (en) *	1992-12-02	1994-07-19	Guilford Pharmaceuticals Inc.	ω-[2-(tetrazolylalkyl)cyclohexyl]-2-aminoalkanoic acids as antagonists of excitatory amino acid receptors
US5342946A (en) *	1992-12-02	1994-08-30	Guilford Pharmaceuticals Inc.	Phosphonoalkylquinolin-2-ones as novel antagonists of non-NMDA ionotropic excitatory amino acid receptors
GB9325360D0 (en) *	1993-12-10	1994-02-16	Univ Bristol	Organic compounds
US5489717A (en) *	1994-07-08	1996-02-06	Warner-Lambert Company	Glutamate (NMDA) receptor antagonists
US7354955B2 (en) *	2004-01-07	2008-04-08	Abbott Laboratories	(2S)-amino(phenyl)acetic acid and derivatives as α2δ voltage-gated calcium channel ligands
US20050148671A1 (en) *	2004-01-07	2005-07-07	Chih-Hung Lee	(2S)-amino(phenyl)acetic acid and derivatives as alpha2delta voltage-gated calcium channel ligands
EP3427729A1 (fr)	2017-07-13	2019-01-16	Paris Sciences et Lettres - Quartier Latin	Probénécide destiné à être utilisé dans le traitement de maladies, troubles ou états épileptiques

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BE550634A (fr) *	1955-08-30
US2966074A (en) *	1958-10-29	1960-12-27	Houdaille Industries Inc	Viscous torsional vibration damper
US3754085A (en) *	1971-07-19	1973-08-21	Merck & Co Inc	Phosphonic acid anti-fibrinolytic agents
SU431171A1 (ru) *	1972-09-27	1974-06-05	С. Н. Еременко, Н. С. Фрумина, А. М. Лукин, Г. Б. Заварихина	СПОСОБ ПОЛУЧЕНИЯ n-ФOCФOHOФEHИЛAHTPAHJИЛOBOЙ1Изобретение относитс к способу получени производного фенил антраниловой кислоты, содержащего фосфоногруппу ^в га-положении по отношению к аминному азоту, которое может найти применение в аналитической хи'мии. 5Известен способ получени различных замещенных фенилантраниловой кислоты, например днфениламино-3-сульфо-2'-карбоновой кислоты, нагреванием солей о-хлорбензойной кислоты и сульфаниловой кислоты с поташом ю в присутствии порощ.ка меди в за1па нной трубке.Предлагаемый способ получени п-фосфо- нофенилантраниловой кислоты заключаетс в конденсации п-аминафенилфосфоновой кислоты с о-хлорбензойной кислотой в ще.лочной среде в присутствии порошха .меди или ее солей в качестве катализатора при нагревании, например до 120—130°С, с последующим выделением целевого продукта известными приемами.Реакци протекает по схеме:Ct, .^а.,СОзCUS04 t",СООМа•NaCl
DE2459491A1 (de) *	1974-12-17	1976-06-24	Bayer Ag	Gegenueber isocyanaten reaktive phosphorhaltige flammschutzmittel

1986
- 1986-04-09 US US06/849,696 patent/US4657899A/en not_active Expired - Fee Related
1987
- 1987-02-25 JP JP62501875A patent/JPH01500513A/ja active Pending
- 1987-02-25 WO PCT/US1987/000444 patent/WO1987006131A1/fr not_active Ceased
- 1987-02-25 AU AU71667/87A patent/AU7166787A/en not_active Abandoned
- 1987-03-20 CA CA000532659A patent/CA1297492C/fr not_active Expired - Lifetime
- 1987-04-08 EP EP87105189A patent/EP0242709A3/fr not_active Ceased

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHEM PHARM BULL=1984 *

Also Published As

Publication number	Publication date
WO1987006131A1 (fr)	1987-10-22
EP0242709A2 (fr)	1987-10-28
EP0242709A3 (fr)	1989-07-26
US4657899A (en)	1987-04-14
CA1297492C (fr)	1992-03-17
AU7166787A (en)	1987-11-09

Publication	Publication Date	Title
JPH01500513A (ja)	1989-02-23	特異的興奮性アミノ酸神経伝達物質受容体の拮抗物質
US4761405A (en)	1988-08-02	Antagonists of specific excitatory amino acid neurotransmitter receptors having increased potency
NL8702485A (nl)	1988-05-16	Gesubstitueerde alfa-aminozuren, werkwijzen voor hun bereiding en farmaceutische preparaten die ze bevatten.
JPH05170792A (ja)	1993-07-09	ホスホノ／ビアリール置換ジペプチド誘導体
JPH10508858A (ja)	1998-09-02	改良抗ウイルス性プロドラッグ
EP1685142B1 (fr)	2008-01-09	Derives d'acide phosphinique, inhibiteurs de la beta-secretase pour le traitement de la maladie d'alzheimer
CS9003174A2 (en)	1991-11-12	Derivatives of dtpa complexes, pharmaceuticals that contain these compounds, their application and method of their production
US5273990A (en)	1993-12-28	Phosphono substituted tetrazole derivatives
CA2962922A1 (fr)	2016-04-07	Modulateurs du recepteur de la sphingosine -1-phosphate pour le traitement de troubles cardio-pulmonaires
EP0569333A2 (fr)	1993-11-10	Nouveaux acides N-aralkyl et N-hétéroaralkylamino alcane phosphoniques
DE69514919T2 (de)	2000-06-29	Phosphinsäure-derivate
DE60006706T2 (de)	2004-08-19	N-arylmethylthioanilid-derivate für die hemmung der hiv-replikation
JPH05247069A (ja)	1993-09-24	アミノアルカンホスフィン酸およびその塩
WO2009119858A1 (fr)	2009-10-01	Composé benzénique et son utilisation à des fins médicales
JP2979054B2 (ja)	1999-11-15	骨関節疾患の治療に有用なｎ−〔｛４，５−ジヒドロキシ−及び４，５，８−トリヒドロキシ−９，１０−ジヒドロ−９，１０−ジオキソ−２−アントラセン−イル｝カルボニル〕アミノ酸
US5489717A (en)	1996-02-06	Glutamate (NMDA) receptor antagonists
AU686722B2 (en)	1998-02-12	Heterocyclic compounds
DE69310524T2 (de)	1997-12-04	Phosphono substituierte tetrazol-derivate
JP3045354B2 (ja)	2000-05-29	チオキサンテノン類およびその抗腫瘍剤
CN1420885A (zh)	2003-05-28	治疗用cck抑制剂的新盐,它们的制备方法以及含有它们的药物制剂
US20120264716A1 (en)	2012-10-18	Phenyl bicyclic methyl amine derivatives as sphingosine-1 phosphate receptors modulators
ES2341254T3 (es)	2010-06-17	Derivados de acido fosfinico.
LU80671A1 (de)	1980-01-22	Peptidderivate und deren herstellung
JPS63119423A (ja)	1988-05-24	ベンゼンおよびチオフェン―カルボチオ酸２―アミノアルキルエステル酸塩からなる粘液溶解剤
JPS5810565A (ja)	1983-01-21	トリプトフアン誘導体及びその製法